Correlation Between Catalyst Pharmaceuticals and Iteos Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Catalyst Pharmaceuticals and Iteos Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Catalyst Pharmaceuticals and Iteos Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Catalyst Pharmaceuticals and Iteos Therapeutics, you can compare the effects of market volatilities on Catalyst Pharmaceuticals and Iteos Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Catalyst Pharmaceuticals with a short position of Iteos Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Catalyst Pharmaceuticals and Iteos Therapeutics.

Diversification Opportunities for Catalyst Pharmaceuticals and Iteos Therapeutics

-0.55
  Correlation Coefficient

Excellent diversification

The 3 months correlation between Catalyst and Iteos is -0.55. Overlapping area represents the amount of risk that can be diversified away by holding Catalyst Pharmaceuticals and Iteos Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Iteos Therapeutics and Catalyst Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Catalyst Pharmaceuticals are associated (or correlated) with Iteos Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Iteos Therapeutics has no effect on the direction of Catalyst Pharmaceuticals i.e., Catalyst Pharmaceuticals and Iteos Therapeutics go up and down completely randomly.

Pair Corralation between Catalyst Pharmaceuticals and Iteos Therapeutics

Given the investment horizon of 90 days Catalyst Pharmaceuticals is expected to generate 0.42 times more return on investment than Iteos Therapeutics. However, Catalyst Pharmaceuticals is 2.38 times less risky than Iteos Therapeutics. It trades about 0.1 of its potential returns per unit of risk. Iteos Therapeutics is currently generating about -0.21 per unit of risk. If you would invest  1,974  in Catalyst Pharmaceuticals on September 2, 2024 and sell it today you would earn a total of  233.00  from holding Catalyst Pharmaceuticals or generate 11.8% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthVery Weak
Accuracy100.0%
ValuesDaily Returns

Catalyst Pharmaceuticals  vs.  Iteos Therapeutics

 Performance 
       Timeline  
Catalyst Pharmaceuticals 

Risk-Adjusted Performance

7 of 100

 
Weak
 
Strong
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Catalyst Pharmaceuticals are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unfluctuating basic indicators, Catalyst Pharmaceuticals may actually be approaching a critical reversion point that can send shares even higher in January 2025.
Iteos Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Iteos Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in January 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Catalyst Pharmaceuticals and Iteos Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Catalyst Pharmaceuticals and Iteos Therapeutics

The main advantage of trading using opposite Catalyst Pharmaceuticals and Iteos Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Catalyst Pharmaceuticals position performs unexpectedly, Iteos Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Iteos Therapeutics will offset losses from the drop in Iteos Therapeutics' long position.
The idea behind Catalyst Pharmaceuticals and Iteos Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.

Other Complementary Tools

Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Fundamental Analysis
View fundamental data based on most recent published financial statements
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals